Table 1.

Demographic and clinical features in patients with SSc with anti-Th/To and anticentromere antibodies (ACA).

CharacteristicAnti-Th/To, n = 8ACA, n = 67p
Demographic
  Female:male5:366:10.0006
  Mean age, yrs (± SD)54.5 (± 17.9)66.6 (± 10.1)0.0046
  Mean disease duration, yrs (± SD)8.5 (± 6.5)8.7 (± 5.9)NS
  Limited SSc (lcSSc), %10098.5NS
  Mean time from Raynaud’s phenomenon to SSc onset*, yrs (range)6 (1–24)9 (1–47)NS
Skin involvement, %
  Telangiectasia12.5490.048
  Puffy hands62.528NS
  Digital ulcers5055NS
  Capillaroscopic changes10079*NS
  Calcinosis12.528NS
Cardiopulmonary involvement, %
  Pericarditis254.50.028
  Interstitial lung disease (by chest radiograph)384.50.044
  Pulmonary arterial hypertension010NS
Pulmonary function tests
  FVC onset, mean % ± SD95.3 ± 18.8114.1 ± 18.60.0183
  Last FVC, mean % ± SD97.2 ± 20.5114.7 ± 20.20.0298
  DLCO onset, mean % ± SD81.1 ± 17.274.4 ± 18.9NS
  Last DLCO, mean % ± SD68.7 ± 14.564.6 ± 16.3NS
  % of DLCO at onset vs at the last evaluationp = 0.0925p < 0.0001
  • * Defined by onset of first non-Raynaud feature of SSc disease. NS: nonsignificant. FVC: forced vital capacity; DLCO: diffusion capacity for carbon monoxide.